journal

Journal For International Medical Graduates

California Institute of Behavioral Neurosciences and Psychology

US https://www.cibnp.com

2832-9864

Articles

Renal Manifestations in Juvenile Idiopathic Arthritis (JIA) and the Use of Monoclonal Antibodies for Its Treatment: A Systematic Review

Umaima Fatima

Fatima

Umaima

umaima.fatima@jimgs.com

Aaiyat Sheikh

Sheikh

Aaiyat

aaiyat.sheikh@jimgs.com

Chaitanya S. Puvvada

Puvvada

Chaitanya S.

chaitanya.s.puvvada@jimgs.com

Faiza H. Soomro

Soomro

Faiza H.

faiza.h.soomro@jimgs.com

Hafsa A. Osman Merna Haridi

Merna Haridi

Hafsa A. Osman

hafsa.a..osman.merna.haridi@jimgs.com

Natalie A. Gonzalez

Gonzalez

Natalie A.

natalie.a.gonzalez@jimgs.com

Sana M. Dayo

Dayo

Sana M.

sana.m.dayo@jimgs.com

Ann Kashmer Yu

Ann Kashmer

ann.kashmer.yu@jimgs.com

06 06 2023

Received: 662023

2023

Journal For International Medical Graduates

Juvenile idiopathic arthritis Renal manifestations Nephropathy Nephropathy Nephropathy Tocilizumab

Zaripova LN, Midgley A, Christmas SE, Beresford MW, Baildam EM, Oldershaw RA. Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. Pediatr Rheumatol Online J. 2021;19(1):135. doi:10.1186/s12969-021-00629-8.

Lin CH, Lin CL, Shen TC, Wei CC. Epidemiology and risk of juvenile idiopathic arthritis among children with allergic diseases: a nationwide population-based study. Pediatr Rheumatol Online J. 2016;14(1):15. doi:10.1186/s12969-016-0074-8.

Huang Z, Lee PY, Yao X, Zheng S, Li T. Tofacitinib treatment of refractory systemic juvenile idiopathic arthritis. Pediatrics. May 2019;143(5):e20182845. doi:10.1542/peds.2018-2845.

Parola C, Neumeier D, Reddy ST. Integrating high-throughput screening and sequencing for monoclonal antibody discovery and engineering. Immunology. 2018;153(1):31-41. doi:10.1111/imm.12838.

Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi:10.1136/bmj.d5928.

Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, Stephenson M, Aromataris E. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020;18(10):2127-2133. doi:10.11124/JBISRIR-D-19-00099.

Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4:5. doi:10.1186/s41073-019-0064-8.

Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009, 6:e1000097. 10.1371/journal.pmed.1000097

9 Chantarogh S, Vilaiyuk S, Tim-Aroon T, Worawichawong S. Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: BMC Nephrol. 2017;18(1):159. doi:10.1186/s12882-017-0573-y..

Maleknejad M, Moshari J, Azarfar A, Esmaeili M, Zabolynejad N, Rezayi Yazdi Z, Ghane Sharbaf F. Renal amyloidosis due to juvenile rheumatoid arthritis occurring in early childhood. J Pediatr Nephrol. 2015;3(2):79-81. doi:10.22037/jpn.v3i2.8203.

Kwiatkowska M, Jednacz E, Rutkowska-Sak L. Juvenile idiopathic arthritis complicated by amyloidosis with secondary nephrotic syndrome - effective treatment with tocilizumab. Reumatologia. 2015;53(3):157-160. doi:10.5114/reum.2015.53138.

Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkowska-Sak L, Schneider R, Berkun Y, Calvo I, Erguven M, Goffin L, Hofer M, Kallinich T, Oliveira SK, Uziel Y, Viola S, et al; PRCSG. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396-2406. doi:10.1056/NEJMoa1205099.

De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, Cuttica R, Ravelli A, Schneider R, Woo P, Wouters C, Xavier R, Zemel L, Baildam E, Burgos-Vargas R, Dolezalova P, Garay SM, Merino R, Joos R, Grom A, et al; PRCSG. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385-2395. doi:10.1056/NEJMoa1112802.

Huang Z, Lee PY, Yao X, Zheng S, Li T. Tofacitinib Treatment of Refractory Systemic Juvenile Idiopathic Arthritis. Pediatrics. 2019;143(5):e20182845. doi:10.1542/peds.2018-2845.

Marzan KA. Role of adalimumab in the management of children and adolescents with juvenile idiopathic arthritis and other rheumatic conditions. Adolesc Health Med Ther. 2012;3:85-93. doi:10.2147/AHMT.S22607.